ClinicalTrials.gg
CompletedNCT04407234Updated Jan 8, 2024Results posted

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

A Phase 1 interventional study of Tirzepatide and Acetaminophen in Overweight, Obesity and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-08.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
79th of 104
36 · median 69
Started
2020
with 2 others
Phase 1
12 of 104
5 open now
Registered
4th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 79th largest by enrollment, is one of 3 that started in 2020, is one of 12 in phase 1, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.

The study will last about 13 weeks for each participant, including screening.

03

Conditions studied

  • Overweight
  • Obesity
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 36 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Have a (BMI) between 27 to 45 kilograms per meter squared (kg/m²), inclusive at screening
  • For nondiabetic subjects: as determined by medical history, physical examination, and safety assessments at screening
  • For participants with a confirmed type 2 diabetes diagnosis: The condition must be managed either by diet and exercise alone or on a stable dose of metformin for the past 3 months
  • Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff

Key Exclusion Criteria

  • Have undergone gastric bypass or bariatric surgery
  • Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening
  • For participants with a confirmed type 2 diabetes diagnosis: Have experienced more than 1 episode of severe low blood sugar that require emergency treatment, hospitalization or third parties to administer rescue treatment, in the past 6 months
  • Have any lifetime history of a suicide attempt
  • Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study
  • Unwilling to comply with smoking and alcohol restrictions during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Tirzepatide + Acetaminophen

    Participants received 5mg tirzepatide on Day 1 and Day 8; 10 mg tirzepatide on Day 15, 22 and 29; 15 mg tirzepatide on Day 36 administered subcutaneously (SC) and 160 mg acetaminophen administered orally on Day -1, Day 2 and Day 37.

    Drug: Tirzepatide · Drug: Acetaminophen

Interventions

  • Tirzepatide administered SC.

    Also known as: LY3298176

  • DrugAcetaminophen

    Acetaminophen administered orally.

07

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen

    Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen

    Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37

  2. PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen

    Maximum Observed Drug Concentration (cmax) of Acetaminophen

    Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37

Secondary outcomes

  1. Hemoglobin A1c (HbA1c) Data by Diabetic Status

    Levels of Hemoglobin A1c (HbA1c) were assessed at predose on Day 29, and at follow-up (Day 64).

    Time frame: Predose on Day 29 and follow-up (Day 64)

  2. PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For Non-diabetic

    Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen at Steady State For Non-diabetic

    Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For T2DM

    Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen at Steady State For T2DM

    Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37

  4. PK: Cmax of Acetaminophen at Steady State Non-diabetic

    PK: Cmax of Acetaminophen at Steady State Non-diabetic

    Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37

  5. PK: Cmax of Acetaminophen at Steady State For T2DM

    PK: Cmax of Acetaminophen at Steady State T2DM

    Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37

08

Results

Posted Jan 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneNon-DiabeticType 2 Diabetes Mellitus (T2DM)
Started1818
Received at least one dose of study drug1818
Completed1515
Not completed33
Withdrew: Adverse event33

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen

Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen

Time frame:
Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
Reported as:
Geometric mean · nanograms*hours per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen
nanograms*hours per milliliter (ng*h/mL)Reference:160 mg Acetaminophen (Day -1)Test: 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2)Test: 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen49384 (43635 to 55890)43523 (38456 to 49257)57049 (50171 to 64869)
Statistical analysis
  • Reference:160 mg Acetaminophen (Day -1) vs Test: 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) · Wilcoxon signed rank test · Ratio of geometric least squares mean: 0.881 · 90% CI 0.803 to 0.967
  • Reference:160 mg Acetaminophen (Day -1) vs Test: 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) · Wilcoxon signed rank test · Ratio of geometric least squares mean: 1.16 · 90% CI 1.05 to 1.28
PrimaryPK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen

Maximum Observed Drug Concentration (cmax) of Acetaminophen

Time frame:
Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen
nanograms per milliliter (ng/mL)Reference:160 mg Acetaminophen (Day -1)Test: 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2)Test: 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37
PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen11925 (10566 to 13460)5314 (4708 to 5998)8099 (7111 to 9225)
Statistical analysis
  • Reference:160 mg Acetaminophen (Day -1) vs Test: 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) · Wilcoxon signed rank test · Ratio of geometric least squares mean: 0.446 · 90% CI 0.390 to 0.509
  • Reference:160 mg Acetaminophen (Day -1) vs Test: 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37 · Wilcoxon signed rank test · Ratio of geometric least squares mean: 0.679 · 90% CI 0.589 to 0.783
SecondaryHemoglobin A1c (HbA1c) Data by Diabetic Status

Levels of Hemoglobin A1c (HbA1c) were assessed at predose on Day 29, and at follow-up (Day 64).

Time frame:
Predose on Day 29 and follow-up (Day 64)
Reported as:
Mean · Percentage of HbA1c
Hemoglobin A1c (HbA1c) Data by Diabetic Status
Percentage of HbA1cNon-DiabeticT2DM
Day 29 ± 15.37 ± 0.457.27 ± 0.79
Day 64 ± 1 (Follow-Up)5.29 ± 0.456.87 ± 0.75
SecondaryPK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For Non-diabetic

Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen at Steady State For Non-diabetic

Time frame:
Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
Reported as:
Geometric least squares mean · nanograms*hours per milliliter (ng*h/mL)
PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For Non-diabetic
nanograms*hours per milliliter (ng*h/mL)Reference (Non-diabetic):160 mg Acetaminophen (Day -1)Test (Non-diabetic): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2)Test (Non-diabetic): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37)
PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For Non-diabetic44350 (37276 to 52766)39389 (33107 to 46864)54735 (45695 to 65563)
Statistical analysis
  • Reference (Non-diabetic):160 mg Acetaminophen (Day -1) vs Test (Non-diabetic): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) · Ratio of geometricleast squares mean: 0.888 · 90% CI 0.778 to 1.01
  • Reference (Non-diabetic):160 mg Acetaminophen (Day -1) vs Test (Non-diabetic): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) · Ratio of geometricleast squares mean: 1.23 · 90% CI 1.07 to 1.42
SecondaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For T2DM

Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen at Steady State For T2DM

Time frame:
Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
Reported as:
Geometric least squares mean · nanograms*hours per milliliter (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For T2DM
nanograms*hours per milliliter (ng*h/mL)Reference (T2DM):160 mg Acetaminophen (Day -1)Test (T2DM): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2)Test (T2DM): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For T2DM54989 (46219 to 65424)48090 (40420 to 57215)59440 (49623 to 71199)
Statistical analysis
  • Reference (T2DM):160 mg Acetaminophen (Day -1) vs Test (T2DM): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) · Ratio of geometricleast squares mean: 0.875 · 90% CI 0.766 to 0.999
  • Reference (T2DM):160 mg Acetaminophen (Day -1) vs Test (T2DM): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) · Ratio of geometricleast squares mean: 1.08 · 90% CI 0.938 to 1.25
SecondaryPK: Cmax of Acetaminophen at Steady State Non-diabetic

PK: Cmax of Acetaminophen at Steady State Non-diabetic

Time frame:
Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
Reported as:
Geometric least squares mean · nanograms per milliliter (ng/mL)
PK: Cmax of Acetaminophen at Steady State Non-diabetic
nanograms per milliliter (ng/mL)Reference (Non-diabetic):160 mg Acetaminophen (Day -1)Test (Non-diabetic): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2)Test (Non-diabetic): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37)
PK: Cmax of Acetaminophen at Steady State Non-diabetic10255 (8680 to 12115)4646 (3932 to 5489)8245 (6891 to 9866)
Statistical analysis
  • Reference (Non-diabetic):160 mg Acetaminophen (Day -1) vs Test (Non-diabetic): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) · Ratio of geometricleast squares mean: 0.453 · 90% CI 0.376 to 0.545
  • Reference (Non-diabetic):160 mg Acetaminophen (Day -1) vs Test (Non-diabetic): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) · Ratio of geometricleast squares mean: 0.804 · 90% CI 0.660 to 0.979
SecondaryPK: Cmax of Acetaminophen at Steady State For T2DM

PK: Cmax of Acetaminophen at Steady State T2DM

Time frame:
Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
Reported as:
Geometric least squares mean · nanograms per milliliter (ng/mL)
PK: Cmax of Acetaminophen at Steady State For T2DM
nanograms per milliliter (ng/mL)Reference (T2DM):160 mg Acetaminophen (Day -1)Test (T2DM): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2)Test (T2DM): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37)
PK: Cmax of Acetaminophen at Steady State For T2DM13868 (11738 to 16385)6078 (5144 to 7181)7954 (6648 to 9517)
Statistical analysis
  • Reference (T2DM):160 mg Acetaminophen (Day -1) vs Test (T2DM): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) · Ratio of geometricleast squares mean: 0.438 · 90% CI 0.364 to 0.527
  • Reference (T2DM):160 mg Acetaminophen (Day -1) vs Test (T2DM): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) · Ratio of geometricleast squares mean: 0.574 · 90% CI 0.471 to 0.698

Adverse events

Collected over Baseline Up To 45 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-diabetic0/18 (0%)0/18 (0%)16/18 (88.9%)
T2DM0/18 (0%)0/18 (0%)16/18 (88.9%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventNon-diabeticT2DM
Decreased appetiteMetabolism and nutrition disorders16/184/18
NauseaGastrointestinal disorders7/1814/18
Abdominal distensionGastrointestinal disorders6/188/18
VomitingGastrointestinal disorders3/187/18
ConstipationGastrointestinal disorders4/182/18
DyspepsiaGastrointestinal disorders1/184/18
Gastrooesophageal reflux diseaseGastrointestinal disorders4/180/18
Back painMusculoskeletal and connective tissue disorders1/184/18
FatigueGeneral disorders1/183/18
HeadacheNervous system disorders3/182/18

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Non-DiabeticT2DMTotal
Mean43.9 ± 10.856.2 ± 5.550.1 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Non-DiabeticT2DMTotal
Female101323
Male8513
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Non-DiabeticT2DMTotal
Hispanic or Latino181836
Not Hispanic or Latino000
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Non-DiabeticT2DMTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American426
White141630
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Non-DiabeticT2DMTotal
United States181836
09

Study locations

1 site
  • Clinical Pharmacology of Miami
    Hialeah, Florida 33014, United States
10

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jan 2021, 3 months.

Results were first posted in Jan 2024, 3 years after primary completion.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
May 29, 2020
StartActual
Sep 15, 2020
Primary completionActual
Jan 7, 2021
CompletionActual
Jan 7, 2021
Results first posted
Jan 8, 2024
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04407234
Responsible party
Sponsor
First posted
May 29, 2020
Start date
Sep 15, 2020
Primary completion
Jan 7, 2021
Completion
Jan 7, 2021
Results posted
Jan 8, 2024
Last update
Jan 8, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion